A Phase 1 study of the novel gamma-secretase inhibitor PF-03084014 in patients with T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma

Blood Cancer J. 2015 Sep 25;5(9):e350. doi: 10.1038/bcj.2015.80.
No abstract available

Publication types

  • Clinical Trial, Phase I
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Antineoplastic Agents / pharmacokinetics
  • Antineoplastic Agents / therapeutic use*
  • Female
  • High-Throughput Nucleotide Sequencing
  • Humans
  • Male
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy*
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • Receptor, Notch1 / genetics
  • Tetrahydronaphthalenes / therapeutic use*
  • Valine / analogs & derivatives*
  • Valine / therapeutic use
  • Young Adult

Substances

  • Antineoplastic Agents
  • NOTCH1 protein, human
  • Receptor, Notch1
  • Tetrahydronaphthalenes
  • Valine
  • nirogacestat

Associated data

  • ClinicalTrials.gov/NCT00878189